Obtaining a blood draw has officially become an FDA-cleared method to screen for Alzheimer’s disease. In August 2026, the U.S. Food and Drug Administration greenlit two additional blood diagnostics designed to spot brain alterations tied to Alzheimer’s in adults experiencing cognitive symptoms. This milestone brings the aggregate count of FDA-cleared assays to four within a span of roughly 15 months.

This represents a radical transformation in how clinicians diagnose Alzheimer’s disease. Historically, confirming the condition in a living patient required an invasive spinal tap or a costly amyloid PET scan.

Nevertheless, an Alzheimer’s blood test can easily be misinterpreted by both patients and medical professionals alike.

Below is a breakdown of what these diagnostics measure, their respective accuracy rates, candidate criteria, and what a specific outcome does and does not signify.

Four Alzheimer’s Blood Tests Are Now FDA-Cleared

Each assay serves a distinct intended application:

  • Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio), May 2025. Recognized as the inaugural FDA-cleared Alzheimer’s blood test, this targets adults aged 55 and older undergoing cognitive decline evaluations. It relies on dual cutoffs, yielding positive, negative, or indeterminate outcomes. Among 499 cognitively impaired adults, 92% of positive and 97% of negative results correlated with PET or spinal fluid data, with under 20% falling into indeterminate zones.
  • Elecsys pTau181 (Roche), October 2025. This marked the first assay cleared for primary care deployment, focusing on symptomatic adults 55 and older. Engineered exclusively to rule out Alzheimer’s pathology rather than confirm it, a 312-person study proved its negative outcomes accurate 98% of the time.
  • Elecsys pTau217 (Roche, alongside Eli Lilly), August 2026. The initial single-biomarker blood test authorized to either rule amyloid pathology in or out. Tailored for primary or specialty care environments involving adults 55 and up presenting with cognitive decline complaints or signs. An analysis spanning 2,148 individuals across five research groups differentiated those with and without amyloid on PET scans, achieving an accuracy score of 0.88 among cognitively impaired participants.
  • PrecivityAD2 (C2N Diagnostics), August 2026. The premier test sanctioned for symptomatic adults as young as 40. By utilizing mass spectrometry, it merges amyloid and tau readings into a unified score. Evaluated in 1,142 adults showing cognitive symptoms, 98% of positive findings and 93% of negative findings proved correct.

Crucially, all four diagnostics demand a valid prescription and target individuals already displaying cognitive symptoms. None have clearance to serve as general screening tools for healthy populations.

Alzheimer’s Blood Tests Measure Proteins That Leak From The Brain

The pathology of Alzheimer’s centers on two primary hallmarks: amyloid-beta plaques and tangled structures of abnormally phosphorylated tau proteins. These physical shifts account for the progressive memory loss, spatial and temporal confusion, communication challenges, and behavioral disruptions that impair daily functioning in sufferers.

Such physiological alterations commence developing anywhere from 10 to 20 years prior to memory issues manifesting. Minute concentrations of these signature proteins eventually infiltrate the bloodstream, where advanced laboratory instruments can now quantify them reliably.

Principal markers include phosphorylated tau 217 (p-tau217), phosphorylated tau 181 (p-tau181) utilized in legacy assessments, the amyloid-beta 42/40 ratio, alongside composite ratios like p-tau217 divided by amyloid-beta 42, which help minimize indeterminate outcomes.

The Best Alzheimer’s Blood Tests Are Accurate, But Not All Tests Are Equal

The highest-performing tests boast impressive efficacy. In a pivotal trial, a p-tau217 blood assay matched or exceeded the clinical performance of FDA-approved spinal fluid tests in identifying Alzheimer’s pathology.

However, three vital caveats require consideration.

  1. An Alzheimer’s blood test is not a monolith. A 2025 meta-analysis encompassing 31 specialty-care blood assays revealed sensitivity ratings stretching from roughly 49% to 91%, alongside specificity ranging from 62% to 97%. Consequently, reliability fluctuates based on the specific marker and laboratory platform, restricting results to the exact assay deployed.
  2. Numerous diagnostics categorize results into three tiers rather than two. Outcomes may present as positive, negative, or intermediate. Elite assays deliver definitive answers for roughly 80% or more of patients, leaving the remainder requiring a spinal fluid test or amyloid PET scan to secure a diagnosis.
  3. Context is paramount. A positive result carries significantly more weight in a patient exhibiting clear memory decline at a specialized clinic compared to a low-risk individual with ambiguous complaints. Because validation research primarily occurred in specialty settings, empirical data originating from primary care—where patient demographics and disease prevalence vary—remains scarce.

Alzheimer’s Blood Tests Are For People With Symptoms, After A Full Workup

The Alzheimer’s Association’s 2025 clinical practice guideline—the inaugural framework for these diagnostics—applies exclusively to patients displaying cognitive impairment within specialized memory care settings. It endorses tests exhibiting a minimum of 90% sensitivity and 75% specificity for ruling Alzheimer’s out, alongside at least 90% in both metrics if meant to replace PET or spinal fluid testing.

The current framework omits guidance regarding asymptomatic individuals or those with ambiguous symptoms frequently encountered in primary care. Although the FDA has subsequently cleared primary care tests, official clinical guidelines for general practitioners are still under development.

Furthermore, the guidelines explicitly state that a blood test should never precede a comprehensive clinical evaluation. This thorough workup encompasses medical histories gathered from both the patient and an informed proxy, cognitive screenings, medication reviews, and laboratory panels to rule out reversible triggers like thyroid dysfunction or B12 deficiencies. It also incorporates evaluations for depression and sleep disorders, typically paired with baseline brain imaging.

Even following an exhaustive assessment, clinical diagnosis devoid of Alzheimer’s biomarkers remains prone to error. A Swedish study featured in JAMA indicated that primary care physicians accurately identified Alzheimer's 61% of the time, while dementia specialists managed a 73% accuracy rate—contrasting sharply with a 91% accuracy score yielded by blood biomarkers, highlighting their tangible value.

Patients must understand that a blood assay does not constitute a standalone diagnosis. As emphasized by the Alzheimer’s Association, no single test can unilaterally confirm Alzheimer’s disease. A positive indicator merely reveals that Alzheimer’s-associated changes likely exist within the brain; it does not prove those alterations are driving current symptoms, nor does it forecast the velocity of future cognitive decline.

Many older adults harbor baseline amyloid deposits in the brain absent of notable symptoms. While a negative finding renders Alzheimer’s improbable, ongoing cognitive symptoms still necessitate investigation to uncover alternative root causes.

Treatment Decisions Are Driving Demand For Alzheimer’s Blood Tests

Much of the urgency propelling the adoption of Alzheimer’s blood tests stems from anti-amyloid therapeutics like lecanemab (Leqembi) and donanemab (Kisunla). These pharmaceutical interventions are authorized for individuals grappling with mild cognitive impairment or mild dementia tied to Alzheimer’s, provided amyloid pathology is definitively verified prior to treatment initiation.

Nonetheless, the therapeutic benefits remain modest and subject to ongoing debate, accompanied by substantial risks such as localized brain swelling and microhemorrhages known as ARIA, which mandate regular MRI monitoring. Blood assays could streamline and economize the identification of viable treatment candidates.

Historically, eligibility confirmation relied heavily on PET scans or spinal punctures. Clinical practice continues to adapt as blood tests integrate into the prerequisite workflow for these medications.

Even for patients ineligible or disinterested in pharmaceutical treatments, achieving a biologically verified diagnosis aids immensely in personal planning, securing clinical trial enrollment, and concluding a protracted, exhausting search for answers.

Interested patients should consider addressing the following questions with their physician regarding Alzheimer’s blood assays:

  1. Is a blood test appropriate as a component of a comprehensive memory evaluation?
  2. Which exact assay will be utilized, and is it authorized for my specific age demographic and clinical setting?
  3. How will our medical strategy pivot based on the eventual outcome?
  4. If an intermediate result occurs, what is the subsequent step?

Ultimately, Alzheimer’s blood tests offer enhanced accessibility, minimal invasiveness, and superior scalability compared to spinal taps or PET scans. Deployed in the correct patient cohorts, utilizing appropriate assays alongside careful clinical dialogues, these tools can vastly compress a diagnostic timeline that traditionally spans years.

Conversely, careless application risks causing greater confusion than clarity. Given the rapid pace of scientific advancement, clinical guidelines will inevitably evolve as accumulating evidence matures.